Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Stock Information for Inhibikase Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.